High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
Medulloblastoma - Brain Tumors - Neuroectodermal Tumors, Primitive
Conditions: official terms
Brain Neoplasms - Medulloblastoma - Neoplasms - Neuroectodermal Tumors - Neuroectodermal Tumors, Primitive
Conditions: Keywords
Brain PNET
Study Type
Study Phase
Phase 2
Study Design
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Etoposide, carboplatin, melphalan, cisplatin, thiotepa
Type: Drug
Overall Status
The purpose of this study is to evaluate the efficacy of the combination of surgery, conventional chemotherapy, sequential high-dose chemotherapy with peripheral blood stem cell transplantation and reduced dose radiation therapy in high-risk PNET brain tumors.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 10 Years
Minimum Age: N/A
Gender: Both
Criteria: Inclusion Criteria:

- Medulloblastoma in patients less than 5 years of age

- Brain PNET in patients less than 10 years of age

- Histologically documented diagnosis

- Body weight of > 8 kg

Exclusion Criteria:

- Parents' refusal
Institut Gustave Roussy
Villejuif, France
Status: Recruiting
Contact: Chantal Kalifa, MD - 33 1 42 11 4166 - kalifa@igr.fr
Start Date
July 2002
Gustave Roussy, Cancer Campus, Grand Paris
Gustave Roussy, Cancer Campus, Grand Paris
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page